Nisha Bansal1, Adam Szpiro2, Kristi Reynolds3, David H Smith4, David J Magid5, Jerry H Gurwitz6, Frederick Masoudi7, Robert T Greenlee8, Grace H Tabada9, Sue Hee Sung9, Ashveena Dighe1, Alan S Go9,10,11,12. 1. Kidney Research Institute, Division of Nephrology, University of, Seattle. 2. Department of Biostatistics, University of Washington, Seattle. 3. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena. 4. Kaiser Permanente Northwest Center for Health Research, Portland, Oregon. 5. Department of Medicine, Kaiser Permanente Colorado, Denver. 6. Meyers Primary Care Institute, Worcester, Massachusetts. 7. University of Colorado Hospital, Aurora. 8. Marshfield Clinic Research Foundation, Marshfield, Wisconsin. 9. Kaiser Permanente Northern California Division of Research, Oakland. 10. Department of Epidemiology, University of California, San Francisco. 11. Department of Biostatistics, University of California, San Francisco. 12. Department of Medicine, University of California, San Francisco.
Abstract
Importance: Chronic kidney disease (CKD) is common in adults with heart failure and is associated with an increased risk of sudden cardiac death. Randomized trials of participants without CKD have demonstrated that implantable cardioverter defibrillators (ICDs) decrease the risk of arrhythmic death in selected patients with reduced left ventricular ejection fraction (LVEF) heart failure. However, whether ICDs improve clinical outcomes in patients with CKD is not well elucidated. Objective: To examine the association of primary prevention ICDs with risk of death and hospitalization in a community-based population of potentially ICD-eligible patients who had heart failure with reduced LVEF and CKD. Design, Settings, and Participants: This noninterventional cohort study included adults with heart failure and an LVEF of 40% or less and measures of serum creatinine levels available from January 1, 2005, through December 31, 2012, who were enrolled in 4 Kaiser Permanente health care delivery systems. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m2. Patients who received and did not receive an ICD were matched (1:3) on CKD status, age, and high-dimensional propensity score to receive an ICD. Follow-up was completed on December 31, 2013. Data were analyzed from 2015 to 2017. Exposures: Placement of an ICD. Main Outcomes and Measures: All-cause death, hospitalizations due to heart failure, and any-cause hospitalizations. Results: A total of 5877 matched eligible adults with CKD (1556 with an ICD and 4321 without an ICD) were identified (4049 men [68.9%] and 1828 women [31.1%]; mean [SD] age, 72.9 [8.2] years). In models adjusted for demographics, comorbidity, and cardiovascular medication use, no difference was found in all-cause mortality between patients with CKD in the ICD vs non-ICD groups (adjusted hazard ratio, 0.96; 95% CI, 0.87-1.06). However, ICD placement was associated with increased risk of subsequent hospitalization due to heart failure (adjusted relative risk, 1.49; 95% CI, 1.33-1.60) and any-cause hospitalization (adjusted relative risk, 1.25; 95% CI, 1.20-1.30) among patients with CKD. Conclusions and Relevance: In a large, contemporary, noninterventional study of community-based patients with heart failure and CKD, ICD placement was not significantly associated with improved survival but was associated with increased risk for subsequent hospitalization due to heart failure and all-cause hospitalization. The potential risks and benefits of ICDs should be carefully considered in patients with heart failure and CKD.
Importance: Chronic kidney disease (CKD) is common in adults with heart failure and is associated with an increased risk of sudden cardiac death. Randomized trials of participants without CKD have demonstrated that implantable cardioverter defibrillators (ICDs) decrease the risk of arrhythmic death in selected patients with reduced left ventricular ejection fraction (LVEF) heart failure. However, whether ICDs improve clinical outcomes in patients with CKD is not well elucidated. Objective: To examine the association of primary prevention ICDs with risk of death and hospitalization in a community-based population of potentially ICD-eligible patients who had heart failure with reduced LVEF and CKD. Design, Settings, and Participants: This noninterventional cohort study included adults with heart failure and an LVEF of 40% or less and measures of serum creatinine levels available from January 1, 2005, through December 31, 2012, who were enrolled in 4 Kaiser Permanente health care delivery systems. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m2. Patients who received and did not receive an ICD were matched (1:3) on CKD status, age, and high-dimensional propensity score to receive an ICD. Follow-up was completed on December 31, 2013. Data were analyzed from 2015 to 2017. Exposures: Placement of an ICD. Main Outcomes and Measures: All-cause death, hospitalizations due to heart failure, and any-cause hospitalizations. Results: A total of 5877 matched eligible adults with CKD (1556 with an ICD and 4321 without an ICD) were identified (4049 men [68.9%] and 1828 women [31.1%]; mean [SD] age, 72.9 [8.2] years). In models adjusted for demographics, comorbidity, and cardiovascular medication use, no difference was found in all-cause mortality between patients with CKD in the ICD vs non-ICD groups (adjusted hazard ratio, 0.96; 95% CI, 0.87-1.06). However, ICD placement was associated with increased risk of subsequent hospitalization due to heart failure (adjusted relative risk, 1.49; 95% CI, 1.33-1.60) and any-cause hospitalization (adjusted relative risk, 1.25; 95% CI, 1.20-1.30) among patients with CKD. Conclusions and Relevance: In a large, contemporary, noninterventional study of community-based patients with heart failure and CKD, ICD placement was not significantly associated with improved survival but was associated with increased risk for subsequent hospitalization due to heart failure and all-cause hospitalization. The potential risks and benefits of ICDs should be carefully considered in patients with heart failure and CKD.
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Fred M Kusumoto; Hugh Calkins; John Boehmer; Alfred E Buxton; Mina K Chung; Michael R Gold; Stefan H Hohnloser; Julia Indik; Richard Lee; Mandeep R Mehra; Venu Menon; Richard L Page; Win-Kuang Shen; David J Slotwiner; Lynne Warner Stevenson; Paul D Varosy; Lisa Welikovitch Journal: J Am Coll Cardiol Date: 2014-05-09 Impact factor: 24.094
Authors: Eric S Williams; Svati H Shah; Jonathan P Piccini; Albert Y Sun; Jason I Koontz; Sana M Al-Khatib; Patrick M Hranitzky Journal: Europace Date: 2011-08-06 Impact factor: 5.214
Authors: Stephen Sidney; Michael Sorel; Charles P Quesenberry; Cynthia DeLuise; Stephan Lanes; Mark D Eisner Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2003-08 Impact factor: 4.749
Authors: Casey S Hager; Sunil Jain; Jeffry Blackwell; Benjamin Culp; Juhee Song; Christopher D Chiles Journal: Am J Cardiol Date: 2010-11-01 Impact factor: 2.778
Authors: Matthew D Solomon; Thomas K Leong; Eleanor Levin; Jamal S Rana; Marc G Jaffe; Stephen Sidney; Sue Hee Sung; Catherine Lee; Anthony DeMaria; Alan S Go Journal: J Am Heart Assoc Date: 2020-03-05 Impact factor: 5.501
Authors: Tariq Ahmad; Lars H Lund; Pooja Rao; Rohit Ghosh; Prashant Warier; Benjamin Vaccaro; Ulf Dahlström; Christopher M O'Connor; G Michael Felker; Nihar R Desai Journal: J Am Heart Assoc Date: 2018-04-12 Impact factor: 5.501
Authors: Alan S Go; Thida C Tan; Rishi V Parikh; Andrew P Ambrosy; Leonid V Pravoverov; Sijie Zheng; Thomas K Leong Journal: BMC Nephrol Date: 2021-09-06 Impact factor: 2.388
Authors: Jayanthi N Koneru; Paul W Jones; Eric F Hammill; Nicholas Wold; Kenneth A Ellenbogen Journal: J Am Heart Assoc Date: 2018-05-10 Impact factor: 5.501
Authors: Markus Zabel; Christian Sticherling; Rik Willems; Andrzej Lubinski; Axel Bauer; Leonard Bergau; Frieder Braunschweig; Josep Brugada; Sandro Brusich; David Conen; Iwona Cygankiewicz; Panagiota Flevari; Milos Taborsky; Jim Hansen; Gerd Hasenfuß; Robert Hatala; Heikki V Huikuri; Svetoslav Iovev; Stefan Kääb; Gabriela Kaliska; Jaroslaw D Kasprzak; Lars Lüthje; Marek Malik; Tomas Novotny; Nikola Pavlović; Georg Schmidt; Tchavdar Shalganov; Rajeeva Sritharan; Simon Schlögl; Janko Szavits Nossan; Vassil Traykov; Anton E Tuinenburg; Vasil Velchev; Marc A Vos; Stefan N Willich; Tim Friede; Jesper Hastrup Svendsen; Béla Merkely Journal: ESC Heart Fail Date: 2018-10-09